NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $100,896 | -18.2% | 175,411 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $123,296 | +84.0% | 175,411 | +735.3% | 0.00% | +100.0% |
| Q3 2022 | $67,000 | -87.2% | 21,000 | -84.8% | 0.00% | -85.7% |
| Q2 2022 | $525,000 | -90.8% | 138,043 | -86.9% | 0.01% | -89.9% |
| Q1 2022 | $5,698,000 | +342.7% | 1,057,400 | +1011.7% | 0.07% | +392.9% |
| Q4 2021 | $1,287,000 | -26.9% | 95,116 | -2.9% | 0.01% | -30.0% |
| Q3 2021 | $1,760,000 | -24.5% | 98,000 | -27.9% | 0.02% | -35.5% |
| Q2 2021 | $2,330,000 | +94.2% | 135,865 | +126.4% | 0.03% | +19.2% |
| Q1 2021 | $1,200,000 | +81.3% | 60,000 | +50.0% | 0.03% | +62.5% |
| Q3 2020 | $662,000 | -64.3% | 40,010 | -50.0% | 0.02% | -74.2% |
| Q2 2020 | $1,854,000 | +57.7% | 80,000 | +21.2% | 0.06% | -6.1% |
| Q1 2020 | $1,176,000 | -31.9% | 66,000 | -17.5% | 0.07% | +13.8% |
| Q4 2019 | $1,728,000 | +136.7% | 80,000 | +100.0% | 0.06% | +52.6% |
| Q3 2019 | $730,000 | +113.5% | 40,000 | +471.4% | 0.04% | +46.2% |
| Q2 2018 | $342,000 | – | 7,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |